Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for eliglustat

  1. Eliglustat for treating type 1 Gaucher disease (HST5)

    Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.

    Highly specialised technologies guidance
    Published
    28 June 2017
    View recommendations

    Sections for HST5

  2. NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type 1 Gaucher disease.

    collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type...

    Research recommendation
    Published
    12 October 2018